Navigation Links
Heptares Announces Positive Outcome of Phase 1A Study with First-ever Selective Muscarinic M1 Receptor Agonist for Improving Cognition in Patients With Alzheimer's Disease
Date:6/16/2015

LONDON and BOSTON, June 17, 2015 /PRNewswire/ --

Early evidence of enhanced brain activity seen at dose levels that are well tolerated 

Heptares Therapeutics, the clinical-stage GPCR structure-guided drug discovery and development company and wholly-owned subsidiary of Sosei Group Corporation, announces the positive outcome of its Phase 1a study with HTL9936, the first-ever fully selective muscarinic M1 receptor agonist to enter clinical development.

"HTL9936 was designed and developed specifically to be a first-in-class oral agent to improve cognitive function (memory and thinking abilities) in patients with serious neurological diseases, such as Alzheimer's disease and dementia," said Tim Tasker, Chief Medical Officer of Heptares. "We are therefore delighted with the outcome of this first clinical study, the results of which provide important validation of our GPCR-directed structure-based design platform and approach to create important new medicines in areas of unmet need. We look forward to advancing HTL9936 and the M1 agonist programme into further clinical studies to confirm the efficacy and safety observed."

The Phase 1a study assessed the safety, tolerability and pharmacokinetics of HTL9936 in relation to dose in 84 healthy volunteers, while also evaluating preliminary signs of efficacy (increase in brain activity). Key findings were:

  • Early evidence of increased brain activity, as measured by electroencephalography (EEG), was seen after dosing and gave signals similar to those seen with other cognitive enhancing agents, such as donepezil and rivastigmine.
  • HTL9936 was well tolerated at drug levels that result in the increased brain activity observed without side effects.
  • HTL9936 demonstrates good penetration into the brain, as indicated by levels found in cerebrospinal fluid.
  • M1 selectivity was demonstrated with, unlike earlier muscarinic agonists, no adverse effects seen from stimulation of other muscarinic receptors.

These preliminary data suggest that the selective M1 agonist product profile of HTL9936 predicted from preclinical studies translates to humans. Heptares is now putting in place a series of further clinical studies with the objective of demonstrating clinical proof of concept in patients, and moreover is advancing its diverse portfolio of follow-on selective muscarinic agonists that target M1, M4, and both M1/M4 to the clinic.

Notes to Editors 

About M1 Receptor Agonism 

M1 receptor agonism is a well-validated mechanism of action for treating cognitive impairment and a valuable pharmacological profile that the pharmaceutical industry has endeavored to create for decades. The principal challenge has been to engineer selective compounds that activate the M1 receptor subtype without also activating the M2 or M3 receptors, which are associated with undesirable side effects. All previous compounds have been discontinued due to inadequate selectivity. Using a new structure-guided approach, Heptares scientists determined for the first time the x-ray crystal structure of the M1 receptor in its agonist conformation and used these unique insights into the receptor drug binding site to identify new chemistries with fully selective M1 agonist profiles.

About Alzheimer's Disease and Other Disorders of Cognitive Impairment 

Today there is significant unmet medical need and heavy economic burden across multiple diseases characterised by cognitive impairment and dementia. In Alzheimer's disease, currently available drugs provide limited and transient effects on cognition. Healthcare costs associated with the epidemic of AD, including nursing home care, continue to grow dramatically and new therapies with better and more durable efficacy are urgently needed. In addition, an estimated 80% of schizophrenics suffer from cognitive impairment and 1.3 million patients in the US suffer from Lewy body dementia. Currently there are no approved therapies for treating cognitive impairment in schizophrenia.

About Heptares Therapeutics 

Heptares is a clinical-stage company creating transformative medicines targeting G protein-coupled receptors (GPCRs), a superfamily of 375 receptors linked to a wide range of human diseases. Our proprietary structure-based drug design technology enables us to engineer drugs for highly validated, yet historically undruggable or challenging, GPCRs. Using this approach, we have built an exciting pipeline of new medicines with the potential to transform the treatment of Alzheimer's disease, schizophrenia, ADHD, migraine, addiction, metabolic disease and other indications. Our pharmaceutical partners include AstraZeneca, MedImmune, Cubist, MorphoSys and Takeda. Heptares is a wholly owned subsidiary of Sosei Group Corporation. For more information, please visit http://www.heptares.com and http://www.sosei.com.

HEPTARES is a registered trademark in the EU, Switzerland, US and Japan;  

StaR is a registered trademark in the EU and Japan. 



'/>"/>
SOURCE Heptares Therapeutics
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. Heptares Augments Business Development Capabilities in Japan and Other Asian Territories
2. Heptares Achieves First Research Milestone in Research Collaboration with Cubist
3. Heptares Initiates Clinical Study With First Selective Muscarinic M1 Receptor Agonist for Improving Cognition in Patients With Alzheimers Disease
4. Heptares to Moderate Panel on Global Business Development at Upcoming Boston Biotech East/West CEO Conference
5. Heptares to Present at CNS Partnering & Deal-making and Biopharm America
6. Heptares to Present on Structure-Based Drug Design Using G Protein-Coupled Receptors at Inaugural Chemistry & Engineering News Virtual Symposium
7. Heptares First-in-Class Selective Muscarinic Agonists Chosen as one of top Neuroscience Projects to Watch
8. Heptares Extends Global Patent Protection for GPCR-Focused Drug Discovery Platform With Grant of Core Patents in the United States
9. Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery
10. Pharmagen Announces First Quarter 2013 Results
11. Aoxing Pharmaceutical Company, Inc. Announces Financial Results For Third Quarter Of 2013 Fiscal Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/19/2019)... Pa. (PRWEB) , ... February 19, 2019 , ... ... Healthcare firms of all sizes, announces the hiring of Frank Iafrato as Director of ... work to deepen the firm’s sales coverage throughout the Northeast region, building upon the ...
(Date:2/19/2019)... ... February 19, 2019 , ... Clearwater Dental Associates is opening ... do not have the proper amount of bone to support a dental implant long-term. ... improve the strength of the jaw bone. , Gum disease and untreated tooth loss ...
(Date:2/19/2019)... CALABASAS, Calif. (PRWEB) , ... February 19, 2019 , ... ... missing teeth in Calabasas, California, to make an appointment at her Simi ... “gold standard” of tooth replacement, as they can last 20 years or longer with ...
Breaking Medicine Technology:
(Date:2/19/2019)... ... February 19, 2019 , ... ... development solutions for drugs, biologics and consumer health products, today announced that ... US Bioassay Conference of the BioPharmaceutical Emerging Best Practices Association (BEBPA), taking ...
(Date:2/19/2019)... ... February 19, 2019 , ... ... Filtration is based in The Villages FL proudly serving over 3,500 satisfied customers. ... Territory in the greater Jacksonville area selling and installing our popular Water Filtration ...
(Date:2/19/2019)... (PRWEB) , ... February 19, 2019 , ... ... with Clover Creek Cultivation LLC , a newly-licensed cannabis cultivation and manufacturing ... hydrocarbon and ethanol extraction, distillation, and ISO-7 product formulation, while Clover Creek is ...
(Date:2/19/2019)... ... 2019 , ... The California Dental Association is pleased to ... as a new member benefit. , Student loan debt is one of ... all indebted graduates in the class of 2018 for public and private dental ...
(Date:2/19/2019)... ... February 19, 2019 , ... ClearHealth Quality Institute (CHQI) ... Lardner LLP, as Recognized Consultants. The CHQI Recognized Consultant Program trains third-parties to ... accreditation. , Ms. Wein and Mr. Einhorn are part of Foley’s Telemedicine ...
Breaking Medicine News(10 mins):